Table 1. Clinical development of IL-17/IL-23 inhibitors in chronic inflammatory diseases.
| Barrier tissues | Nonbarrier tissues | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Target | Drug and trade names | Plaque psoriasis | IBD | Other diseases | PsA | Ankylosing spondylitis | RA | MS | Other diseases |
| IL-17A | Secukinumab (AIN457; Cosentyx) | Approved | Phase II, terminated (ineffective); NCT01009281 (Hueber et al., 2012) | Asthma: Phase II, terminated (ineffective); NCT01478360 | Approved | Approved | Phase III, terminated; NCT01377012 | Phase II, terminated; NCT01051817 (Havrdová et al., 2016) | Diabetes mellitus type 1: Phase II, terminated (business reasons); NCT02044848 |
| Atopic dermatitis: Phase II; NCT02594098 | |||||||||
| Hidradenitis suppurativa: Phase II; NCT03713632 | Giant cell arteritis: Phase II; NCT03765788 | ||||||||
| Pityriasis rubra pilaris: Phase I; NCT03342573 | |||||||||
| IL-17A | Ixekizumab (Taltz) | Approved | Approved | Phase III; NCT02696785 (van der Heijde et al., 2018) | Phase II; NCT00966875 (Genovese et al., 2014) | ||||
| IL-17A | Netakimab (BCD-085) | Phase III; NCT03390101 | Phase III; NCT03598751 | Phase III; NCT03447704 | Primary biliary cirrhosis: Phase II; NCT03476993 | ||||
| IL-17A | CNTO 6785 | Phase II (ineffective); NCT01909427 (Mease et al., 2018b) | |||||||
| IL-17A | CJM112 | Phase I, terminated; NCT01828086 | Asthma: Phase II; NCT03299686 | ||||||
| Hidradenitis suppurativa: Phase II; NCT02421172 | |||||||||
| IL-17A /IL-17F | Bimekizumab | Phase III; NCT03598790 | Hidradenitis suppurativa: Phase II; NCT03248531 | Phase III; NCT03896581; NCT03895203 | Phase III; NCT03928743 | ||||
| IL-17A/IL-17F | M1095 (ALX-0761) | Phase II NCT03384745 | |||||||
| IL-17RA | Brodalumab (Siliq; Kyntheum) | Approved | Phase II, terminated (disease worsening); NCT00966875 (Targan et al., 2016) | Asthma: Phase II, terminated (ineffective); NCT01902290 | Phase III, terminated (sponsor decision); NCT02029495 (Mease et al., 2014) | Phase II, withdrawn (sponsor decision); NCT02429882 | Phase II, terminated (ineffective); NCT00950989 (Pavelka et al., 2015) | ||
| Phase II (ineffective); NCT01199289 (Busse et al., 2013) | |||||||||
| IL-17A/TNF | ABT-122 | Phase II, (ineffective); NCT02349451 (Mease et al., 2018a) | Phase II, (ineffective); NCT02433340, NCT02349451 (Khatri et al., 2019) | ||||||
| IL-17A/TNF | COVA 322 | Phase II, terminated (safety profile); NCT02243787 | |||||||
| IL-17/IL-6 | MT-6194 | Preclinical (Lyman et al., 2018) | |||||||
| IL-17/BAFF | LY3090106 | Phase I; NCT01925157 | Sjögren’s syndrome: Phase I; NCT02614716 | ||||||
| IL-23p19 | Risankizumab (Skyrizi) | Approved | Crohn’s disease: Phase III; NCT03104413, NCT03105102, NCT03105128 | Asthma: Phase II; NCT02443298 | Phase III; NCT03675308, NCT03671148 | Phase II (ineffective); NCT02047110 (Baeten et al., 2018) | |||
| Ulcerative colitis: Phase III; NCT03398148, NCT03398135 | Atopic dermatitis: Phase II; NCT03706040 | ||||||||
| Hidradenitis suppurativa: Phase II; NCT03926169 | |||||||||
| IL-23p19 | Tildrakizumab (Ilumetri; Ilumya) | Approved | Phase II; NCT03552276, NCT02980692 | Phase III; NCT03552276 | |||||
| IL-23p19 | Guselkumab (Tremfya) | Approved | Crohn’s disease: Phase III; NCT03466411 | Phase III; NCT03796858, NCT03158285, NCT03162796 | Phase II (ineffective); NCT01645280 (Smolen et al., 2017) | ||||
| IL-23p19 | Brazikumab (AMG 139) | Phase I; NCT01094093 | Crohn’s disease: Phase III; NCT03961815, NCT03759288 | ||||||
| Ulcerative colitis: Phase II; NCT03616821 | |||||||||
| IL-23p19 | Mirikizumab (LY 3074828) | Phase III; NCT03535194 | Crohn’s disease: Phase III; NCT03926130 | ||||||
| Ulcerative colitis: Phase II; NCT03524092 | |||||||||
Source: https://clinicaltrials.gov if not otherwise specified. NCT, Clinicaltrials.gov identifier.